Encouragingly, the GBM + anti-PD-1 + EMF group, which received a combined OM-100 and anti-PD-1 treatment, showed even more significant effects with greater reductions in tumor volume and weight compared with the group receiving only the anti-PD-1 drug (GBM + anti-PD-1 group) (Fig. 4G, P < 0.01). The gene discussed is PDCD1; the disease is neoplasm.